Business Wire

POLYMATERIA

Share
A Step Forward for the Circular Economy: Polymateria Open-sources Recyclability Data to Show First Plastic Material to Be Both Recyclable and Biodegradable

Polymateria, who in 2020 became the first company to evidence full biodegradation of plastic in the open environment, has today open-sourced data showing that its Biotransformation technology is recyclable as well as biodegradable.

Heralding a step forward in the shift to a more circular economy, polyethylene filmcontaining Polymateria’s Biotransformation technology has been shown to meet accepted industry protocol for recyclability through independent testing.

Polymateria’s technology demonstrates that the vision of a truly circular economy is possible. An economy where materials are reused or recycled as a matter of priority while allowing any items escaping the system to return to nature without causing any harm. By uniquely time-controlling when biodegradation will start, Polymateria’s technology allows time for recycling to take place before biodegradation is triggered.

Through open-sourcing its data, Polymateria invites other companies to work together to build a truly circular economy. The company is looking forward to working with plastic manufacturers, consumer brands and recyclers to unite the value chain and bring the circular economy vision to life.

Biodegradation of material containing Polymateria’s technology is verified by the British Standard Institution’s (BSI) new PAS 9017 standard for the Biodegradation of polyolefins in an open-air terrestrial environment which was launched in late 2020. The first of its kind, the standard sets a series of stringent pass/fail criteria ensuring full biodegradation with no microplastics or ecotoxicity left behind.

The open-sourced recyclability report from Impact Solutions can be found here .

Nial Dunne, CEO of Polymateria, said:

This is a good day for all those who believe in building a circular economy.

For too long, it has been assumed that biodegradable material cannot also be recycled. Our technology is changing perceptions. Products containing our technology should be recycled as a matter of priority, but any items escaping the system will return to nature at the right time without causing any harm.

As enablers of a circular economy, we invite the industry to join the growing number of partners working with us to bring a circular economy vision to life.

Dr Christopher Wallis, Polymateria SVP of Innovations, said:

I am pleased with the technical recyclability results achieved through the independent testing conducted by Impact Solutions. With these results, we can demonstrate that material containing our technology meets current industry protocol for mechanical recycling of polyolefins.

Dr Michail Kalloudis, Director of Polymer Science at Impact Solutions, said:

Our independent research clearly demonstrates that polyethele film containing Polymateria’s Biotransfromation masterbatch is recyclable within normal mechanical recycling streams. We tested the material stringently against recycling industry protocol.

Dr Simon Hepworth, Director of Enterprise at Imperial College London said:

We are delighted to see the progress being made by Polymateria, first at the White City Incubator and now within the Translation & Innovation Hub (I-HUB), joining a range of deep tech companies and remaining part of Imperial's entrepreneurial ecosystem. As a science-focused business developing technology to address global environmental challenges, we're proud to see them flourish and to continue our role in supporting Polymateria's efforts to build a circular economy.

Technical note:

  • Polyethelene film containing Polymateria’s masterbatch technology was tested by Impact Solutions, UK. The report can be accessed here .
  • Recyclability was tested and proven against the Recyclass “Recyclability Assessment Protocols for PE Films ” version 1.0 published on September 6th 2018.

About Polymateria
Polymateria’s mission is to advance science to help nature deal with the plastic pollution crisis. Born from, and now based at, Imperial College London, we’re the first company in the world to prove scientifically that you can take the most likely sources of fugitive or littered plastic and return them to nature without creating microplastics, harming the natural environment or interfering with recycling streams at scale.

The British Standards Institutions’s new BSI PAS 9017 standard ensures claims of biodegradability in the open environment can be properly verified for the first time according to independent pass/fail criteria. The Standard and Polymateria's technology were recently featured in National Geographic magazine: https://www.nationalgeographic.co.uk/environment-and-conservation/2020/11/new-self-destructing-plastic-has-helped-define-a-new-british

In 2020, Puma became the first international brand to incorporate Polymateria’s technology into its shopping bags: https://www.polymateria.com/wp-content/uploads/2020/07/10663-STim_Polymateria_26072020-A.pdf

Polymateria also has a partnership with international chemical giant Clariant (now Avient) to bring the technology to South-East Asia: https://www.clariant.com/en/Corporate/News/2019/10/Clariant-and-Polymateria-launch-partnership-to-bring-new-Biotransformation-technology-to-market-in-S

Pour Les Femmes, the ethical brand founded by actor/activitist Robin Wright and designer Karen Fowler, is the first apparel brand to introduce Polyamteria’s technology into its packaging: https://pourlesfemmes.com/blogs/blog

The company is proud to be a founding signatory of HRH The Prince of Wales’ Terra Carta (Earth Charter) established under the Sutainanble Markets Initiative.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye